Association between levodopa administration and melanoma: A systematic review
DOI:
https://doi.org/10.56294/piii2024355Keywords:
Parkinson, levodopa, melanoma, skin, disease and skinAbstract
Introduction: Parkinson's disease (PD) is a neurodegenerative disease and levodopa is the main drug used in the treatment of this disease. A study conducted in Denmark demonstrated a two-fold higher incidence of malignant melanoma in patients with Parkinson's, but no correlation was found between levodopa treatment and this incidence. Material and methods: The present systematic review used search engines such as pubmed and Google academic to search for articles of the clinical and randomized trial type. Results: The results of the systematic review indicate a complexity in the relationship between levodopa administration, Parkinson's disease, and melanoma risk. The evidence reviewed suggests that levodopa does not appear to be a significant causal factor in the development of melanoma in patients with Parkinson's disease. Despite the problems raised, the well-established therapeutic benefits of levodopa in the management of the symptoms of Parkinson's disease continue to outweigh the potential risk of causing melanoma. Conclusion: The study concludes that there is an increased risk of developing melanoma in patients with Parkinson's disease but that there is no evidence of a causal role of levodopa in increasing this risk or accelerating its growth
References
Cabreira V, Massano J. Doença de Parkinson: Revisão Clínica e Atualização. Acta Med Port. 1 de octubre de 2019;32(10):661–70.
Hayes MT. Parkinson’s Disease and Parkinsonism. The American Journal of Medicine. julio de 2019;132(7):802–7.
Ali K, Morris HR. Parkinson’s disease: chameleons and mimics. Pract Neurol. febrero de 2015;15(1):14–25.
Vermeij JD, Winogrodzka A, Trip J, Weber WEJ. Parkinson’s disease, levodopa-use and the risk of melanoma. Parkinsonism & Related Disorders. septiembre de 2009;15(8):551–3.
Fiala KH, Whetteckey J, Manyam BV. Malignant melanoma and levodopa in Parkinson’s disease: causality or coincidence? Parkinsonism & Related Disorders. agosto de 2003;9(6):321–7.
Niemann N, Billnitzer A, Jankovic J. Parkinson’s disease and skin. Parkinsonism & Related Disorders. enero de 2021;82:61–76.
Olsen JH, Tangerud K, Wermuth L, Frederiksen K, Friis S. Treatment with levodopa and risk for malignant melanoma. Movement Disorders. 15 de julio de 2007;22(9):1252–7.
Levin L, Srour S, Gartner J, Kapitansky O, Qutob N, Dror S, et al. Parkin Somatic Mutations Link Melanoma and Parkinson’s Disease. Journal of Genetics and Genomics. junio de 2016;43(6):369–
Inzelberg R, Rabey JM, Melamed E, Djaldetti R, Reches A, Badarny S, et al. High prevalence of malignant melanoma in Israeli patients with Parkinson’s disease. J Neural Transm. agosto de 2011;118(8):1199–207.
Constantinescu R, Romer M, Kieburtz K, DATATOP Investigators of the Parkinson Study Group.
Malignant melanoma in early Parkinson’s disease:
The DATATOP trial. Movement Disorders. 15 de abril de 2007;22(5):720–2.
Constantinescu R, Elm J, Auinger P, Sharma S, Augustine EF, Khadim L, et al. Malignant melanoma in early‐treated Parkinson’s disease: The NET‐PD trial. Movement Disorders. febrero de 2014;29(2):263–5.
Olsen JH, Tangerud K, Wermuth L, Frederiksen K, Friis S. Treatment with levodopa and risk for malignant melanoma. Movement Disorders. 15 de julio de 2007;22(9):1252–7.
Mancini M, Rocchi L, Horak FB, Chiari L. Effects of Parkinson’s disease and levodopa on functional limits of stability. Clinical Biomechanics. mayo de 2008;23(4):450–8.
Zanetti R, Loria D, Rosso S. Melanoma, Parkinson’s disease and levodopa: causal or spurious link? A review of the literature. Melanoma Research. junio de 2006;16(3):201–6.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Fernanda Luparelli Mello, Marcelo Adrian Estrin (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
